Oxford Nanopore Technologies plc (ONT) Earnings Call Transcript & Summary

March 2, 2026

London Stock Exchange GB Health Care Life Sciences Tools and Services earnings 70 min

Earnings Call Speaker Segments

Duncan Tatton-Brown

executive
#1

Good morning to all of you, and I appreciate your time in joining us today. Ahead of presenting the 2025 results, I want to start by noting a significant milestone in how Oxford Nanopore has developed. As we announced earlier, Gordon Sanghera is stepping down today from the Chief Executive Officer role, having led the business he co-founded back in 2005 for over 2 decades. During Gordon's time in charge, Oxford Nanopore has evolved from an ambitious scientific concept into a platform technology company with global reach, with customers in over 125 countries spanning research, clinical, biopharma and applied industrial markets. Speaking for the Board, I want to express our gratitude to Gordon for the remarkable vision, determination and dedication he showed in establishing the foundations that leave the company well positioned for the next stage of its development. Through to early 2027, he will stay on with the company in an advisory capacity, helping ensure a smooth and orderly transition. Today is also the first day for Francis Van Parys as CEO of Oxford Nanopore. Francis formally joins the company this morning. He is in Oxford today, meeting the team, and so will not be joining us. Once he has had the chance to engage more deeply with the business, we look forward to introducing him to many of you in due course.

Duncan Tatton-Brown

executive
#2

The Board is glad to have Francis on board at this pivotal point in the company's evolution. His background in scaling innovation-driven life sciences businesses—especially in regulated and commercial settings—will help support Oxford Nanopore's continued development. The Board stays focused on maintaining our backing for leading-edge science, driving strong growth across our priority end markets through disciplined execution, and delivering sustainable profits as the business keeps scaling. With that, I'll hand things over to Gordon and Nick, who will walk you through the financial and operational highlights for 2025. Thank you.

Gordon Sanghera

executive
#3

Good morning, everyone. For me, this has been a journey of 21 years. Back in the spring of 2004, I began exploring Hagan Bayley's work on single molecule stochastic sensing. I actually had to look up what "stochastic" meant in a dictionary, but eventually I got the hang of it. As I dug deeper, I grew more and more excited about the possibility of delivering a brand-new measurement method. That kind of opportunity rarely comes along for chemical and biological single molecules. So in 2005, we spun the company out with GBP 0.5 million from IP Group — Dave Norwood at the time — over a pie and a pint. It was simply astonishing that someone would invest that much money in an idea, a concept. Right from the start, the company's vision was to enable the analysis of anything by anyone, anywhere. And I'd say that remains a work in progress. The thing I'm proudest of, and the coolest thing I've witnessed with this technology, is NASA taking it into space — it's slated to go on the Artemis mission as well, which makes me very proud — but also Project NEEMO, where NASA went down into the depths of the Mariana trench and found over 7,500 new species in extreme conditions, which sort of tells us there's life out there somewhere, which is exciting.

Gordon Sanghera

executive
#4

Our initial application area is DNA and RNA. We are now expanding into proteomics, and you will be hearing more about that from Lakmal at London Calling. I will be present there too. But there is also potential for us to measure small molecules, chemicals, metabolites, and volatile organic compounds as well. So this platform has a great deal more to offer in the years ahead. So I want to show some slides, I suppose. That is our vision. You have seen it many times. And as I mentioned, we are just at the start of this journey, with much more to come. We launched our DNA products 10 years ago. And our direct RNA product roughly 5 years ago. As Duncan just mentioned, today we are in more than 125 countries. We have more than 1,300 employees, and we opened our factory because we had a bold ambition from the very beginning that we would deliver a tech company in the U.K. that would manufacture in the U.K. So our consumables, flow cells, and revenues are manufactured in our factory, which we built with an ambitious growth trajectory, meaning that over the next 3 to 5 years, as we grow, we will be able to meet those demands for our consumables.

Gordon Sanghera

executive
#5

What really stands out on this slide is this: across 10 years, ever since our first products came out, we've accumulated 20,000 publications. That's an incredible hit rate. And that decade of innovation is what supports the distinctive value proposition, what this platform for measuring single molecules actually delivers. In this competitive space of ours, no other company sequences DNA and RNA directly. This body of work forms the foundation for our growth. And since the IPO, I'm pleased to report, we've achieved 28% CAGR. That speaks to the unique things, the multiomic direct sequencing of DNA and RNA that only Oxford Nanopore can enable. Once again, 2025 was a strong growth year for us. We delivered 24% growth on a constant currency basis, which is 1% above the top end of our guidance of 23%. Across every region — in a difficult market where competitors over the last 3 or 4 years have experienced low growth, no growth, or negative growth — we achieved 20% growth in all of our regions. 70% of our revenues come from flow cells and kits, which are made in Didcot. And we've stayed financially disciplined this year.

Gordon Sanghera

executive
#6

We hold a bit more than GBP 300 million in cash and cash equivalents, which positions us strongly to continue along our ambitious growth path. As we laid out at capital markets a couple of years ago, we would be shifting from revenues coming entirely from life science research tools toward our applied end markets. In 2025, life science research tools, which represent 66% of our revenues today, grew 15%. To restate that point again, this is significantly outperforming competitors. The applied end market where we grew most strongly was clinical at 59%. BioPharma came in at 30%, and applied industrial at 27%. Year-on-year, that rose from 30% to 34% and is broadly consistent with what we expected to achieve at capital markets a couple of years ago and stands as evidence of the maturing of the platform for our applied end markets. Why are we growing substantially? It isn't a fluke. Luck played no part. 20 years ago, we recognized that single molecule electronic detection of biological polymers could be transformative. And what we deliver with this platform — and we are the only company in the world doing this, including the other Nanopore people — is that we read direct DNA, and we can read short hundreds of bases, long tens of thousands to hundred thousand bases to millions of bases ultra-long.

Gordon Sanghera

executive
#7

That's something no other tech can claim. We're not merely a long-read business. It's that native DNA that sets us apart so strongly. We accomplish this live, in real time, through streaming, since sample preps require hours rather than days. Every other sequencing platform needs days for sample prep. Batching isn't necessary for us, so rapid insights become possible at point of care on distributed, affordable, accessible platforms. Whether it's 1, 2, or all 3 of those attributes, they're what's fueling that robust growth — continuing within our life science research tools market for translational and discovery work, which then serves as the foundation for applied markets. So please keep in mind that adoption is being driven by this technology, and we're very early in this journey. I'll say a bit about Francis at the end, but I'm excited to be handing the baton on to him. And now I'll pass over to Nick, who will get into details and talk about outlook for 2026.

Nicholas Keher

executive
#8

Thank you, Gordon. Good morning, everyone. I'm Nick Keher, CFO of Oxford Nanopore. In today's update, I'll cover our FY '25 financials, our outlook, and how operations performed. FY '25 brought both delivery and further transformation, all within a volatile year. Revenue growth came in at 24.2% at constant currency, slightly above the 20% to 23% guidance we set in March 2025. Every region grew more than 20% on a constant currency basis, and as previously guided, the MinION range also returned to growth. Reported gross margins ended broadly in line with guidance, despite numerous headwinds — some of which should not repeat — and with a see-through gross margin closer to 61%. Adjusted OpEx grew only 1%, which reflects strong cost control during the period along with 2 restructuring events. One took place in January, previously discussed, to allow capital to be reallocated toward higher growth opportunities. The other occurred in November and related to a strategic realignment exercise aimed at aligning the business with these high-priority end markets. As a result, we improved our adjusted EBITDA loss by GBP 31.2 million, or 26%, which is a material step forward on our path to profitability.

Nicholas Keher

executive
#9

We closed out the year with GBP 302.8 million in cash and no debt, which shows a material gain in cash conversion as we improved our business model and concentrated on working capital. And we still expect to hold a minimum cash position of at least GBP 100 million as we move through adjusted EBITDA breakeven in '27 and cash flow breakeven in '28. Moving on to gross margins, the year shows a solid overall improvement, in line with the original guidance of 59% we gave. Starting from a base of 57.5% in FY '24, we achieved underlying gains of 460 bps, powered by the new CapEx-first pricing model; and two, better yields, especially on the PromethION flow cell. While we benefited from improved recycling on the PromethION flow cell, those gains were largely offset during the year by lower recycling levels overall at MinION flow cell. From that position, we then faced FX headwinds of 70 bps, the one-off items discussed earlier tied to obsolete inventory of 150 bps that are not set to repeat, and product and customer mix headwinds of 130 bps. That gave a reported gross margin of 58.6% overall. Within this, we also booked the charge tied to restructuring in the year, almost entirely related to the ElysION product line, of GBP 1.8 million or 80 bps.

Nicholas Keher

executive
#10

Without those items, margin stood at 59.4%, and excluding the one-offs booked in the first half, it would have come in at 60.9%. In our view, that's the number investors and analysts should focus on as we head into FY '26, and we should note there are still several levers to push margin higher in FY '26 and '27 — specifically PromethION flow cell recycling, plus the ongoing gains we're seeing from the pricing model change. Alongside that strong top-line growth and gross margin improvement, we've kept tight discipline on the cost base, with adjusted OpEx up just 1% versus the prior year. As a result, EBITDA improved 26% year-on-year, reaching GBP 31.2 million in total, of which GBP 18 million was generated in the second half — itself a 32% improvement. Zooming out, we've now posted an adjusted EBITDA improvement in every half since the start of FY '24, and we see a solid route to breakeven in '27. It's also worth framing this against the top-line and gross margin headwinds currency has created, which have by now cut our adjusted EBITDA by GBP 9 million since January '24.

Nicholas Keher

executive
#11

We’ll reach breakeven by keeping revenue growth above the market, in line with our historical delivery and what we’re set to do in FY ’26, while continuing to control costs across the cost base. Specifically, we see chances to gain efficiency as we scale through IT, logistics and internal working practices, focusing on non-headcount related expenditures. Moving to cash. Strong operational execution in the year, together with the completed transformation of our business model, has translated into better cash conversion. Our operating loss before restructuring costs was GBP 79.1 million, broadly in line with our EBITDA performance. Restructuring costs of GBP 13.8 million in the year split GBP 5.2 million in the first half and GBP 8.6 million in the second half, stemming from the strategic realignment exercise in November. Working capital was an inflow of GBP 13.4 million, reflecting a meaningful improvement in inventory management, with total inventory levels down GBP 18 million in the period. We continue to see further opportunities for improvement as we look ahead in this area. Assets at customers came in at GBP 10.1 million, down GBP 10.5 million from the prior year, thanks to adoption of the new pricing model. The second half increase of GBP 4.6 million relates primarily to devices for the U.K.

Nicholas Keher

executive
#12

There was also the Biobank contract plus a modest quantity of evaluation devices supplied to customers. Capital expenditures and capitalized development costs came to GBP 45.5 million, divided between GBP 41.5 million for capitalized development and GBP 4 million for CapEx across the business. This low CapEx figure in '25 largely mirrors the timing of investments, and major projects like the Spectrum Building are now finished. A level this low is not likely to recur in '26. Tax income of GBP 18.9 million comes from receiving 2 R&D tax credits during the year, which again is unlikely to repeat in FY '25. Lastly, other investing and financing inflow of GBP 15.3 million represents income from our bond portfolio for the year. So our net cash outflow ended the year at GBP 101 million, which leaves GBP 302.8 million in the bank; with losses coming down and cash conversion improving through our focus on working capital and adoption of the CapEx first approach, we still expect cash reserves of at least GBP 100 million as we move through breakeven. Moving on to commercial strategy: during '25 we finished a strategic review aimed at making sure we maximize the wide-ranging opportunities ahead of us.

Nicholas Keher

executive
#13

The process brought in many viewpoints from within the organization as well as from beyond it, so that we could rank the opportunities that make the strongest use of our differentiated technology to generate value for every one of our stakeholders. During this strategic review, we examined where our right to win is clearest and where we are able to scale with discipline. Looking across research, clinical, biopharma manufacturing QC and additional markets, we found approximately $13 billion to $14 billion of higher priority segments in which our richer data, speed and accessibility deliver a meaningful competitive edge over peer technologies. Next we sort segments into higher, medium and lower priority, judging them not purely by size but by ease of access, differentiation and scalability. That prioritization now shapes everything internally. Commercial resource allocation, product road map decisions, capital deployment and organizational focus. What results is a company that is more focused and more disciplined, concentrating investment behind the segments that drive sustainable growth and margin expansion. With that context, let me turn to how we action these insights in '25. On commercial performance, we delivered GBP 223.9 million of revenue of 24% at constant currency, with growth across all regions and all customer types despite challenging end markets.

Nicholas Keher

executive
#14

What really counts here is the quality of that growth, with clinical close to 60%, biopharma rising 30%, applied industrial at 27%, and research up 15% even with the NIH pressures that continue. That shift in mix toward applied end markets shows how our technology naturally draws these sectors, and our existing investments back that growth. Now that we've sharpened our focus on these end market segments as a corporation, with operational structures aligned as well to enable a strategy, we anticipate additional gains in commercial performance as time goes on. In Clinical, adoption broadened across rare disease and oncology through strategic collaborations like Cepheid and BioMerieux. Across BioPharma and industrial, we backed QC deployment, expansion of plasma sequencing, and greater PromethION utilization. Pricing discipline and contracting structures also grew stronger, lifting both margin profile and cash dynamics. Growth increasingly tilts toward the higher priority segments set out in the strategic review, which gives us confidence in durability as well as operational leverage going forward. On innovation: Gordon already detailed the technical performance gains at the JPM in January, covering advances in output, accuracy, and workflow maturity, and those improvements will keep coming at pace.

Nicholas Keher

executive
#15

However, the main narratives for 2025 center on prioritization and alignment. After the strategic review conducted last year, we sharpened the portfolio so that investment would be concentrated behind the platforms serving our priority end markets best. That involved discontinuing P2 Solo sales starting June this year, directing internal efforts in a focused way toward the P2i, halting any further internal development work on the ElysION platform, and ending direct commercial efforts on that product. Tough calls, but once made. Concentrating on the core platform and integrated systems like the P2i and P24, and pushing Q-line product lines more widely across GridION and PromethION. On GridION, we plan to bring out a version 2 of the Q-Line product in 2026, which addresses a wider set of requirements from our BioPharma customers, while on the Prom, a reassessment of the timeline means the launch date is now updated to late 2027. To make sure our innovation work delivers bigger returns, we are also enhancing how we operate internally, formalizing process improvements so success is more likely. This simplification lowers operational complexity, strengthens capital allocation discipline, and guarantees R&D goes where returns are greatest. Thus innovation in 2025 grew more focused, more commercially aligned, and more scalable.

Nicholas Keher

executive
#16

Regarding operational excellence: from an operations standpoint, 2025 was a story of discipline and leverage. Gross margin kept improving, which came from better pricing, greater flow cell efficiency, and scale in our operations. Across the year, we carried out 2 restructuring events aimed at realigning the organization, simplifying the portfolio, and concentrating R&D on the opportunities with higher ROI. On the operations side, we also pushed automation forward, broadened manufacturing capability, and kicked off ERP and CRM transformation to underpin scalable growth. What this produces is a business that is structurally more focused, with operational leverage that keeps improving. As we look ahead, I would expect additional hires on the executive team to bolster our capabilities and to back our ongoing expansion into these target, higher-priority end markets. Moving to guidance: for FY '26, our revenue guidance is set at between 21% and 25% at constant currency. That guidance sits materially above the end market growth we perceive, with peers largely guiding for low to mid-single-digit growth overall. The growth is being fueled by rising interest in, and demand for, Oxford Nanopore Technologies products, and by customers' wish to see more and do more relative to conventional legacy sequencing technologies. The bottom end of the range reflects the expectation of a research environment in the U.S. that stays subdued, along with specific market dynamics, particularly in China.

Nicholas Keher

executive
#17

On top of that, we've built in some risk stemming from the P2 Solo being discontinued. As usual, we try to risk adjust the guidance so that estimates for the coming year are set in a way that derisks outside expectations. When we look at the top end, it's basically the mirror image of those factors, and we note there's potential to beat this guidance if we manage to convert additional customers over to P2i, which we see as a better product that produces improved outcomes for customers. By region, the strongest growth is expected in the Americas, fueled by ongoing expansion into the applied markets. EMEAI has posted steady, substantial growth. However, in FY '26, we're noting the timing of big research end market contracts rolling off alongside new contracts ramping up, which leads us to anticipate a more cautious growth rate at this stage of the year, and therefore growth that is lower than in '25. Likewise, across APAC, we continue to see -- to expect growth above the end market, but we note the anticipated headwind from the PRECISE II contract coming to an end plus specific factors in China, meaning overall growth could be slower. Relative to our guidance, it's APAC that could be the upside surprise.

Nicholas Keher

executive
#18

Looking ahead to FY '26, we want to observe how the year unfolds from this point. When we break it down by end market, growth remains strongest throughout the applied end markets, once again fueled by clinical and BioPharma. This guidance does not factor in any possible risks arising from the recent events in the Middle East that occurred over the weekend. Right now, our focus is on keeping our people safe, and our thoughts go out to all those affected by the weekend's events, since this risk is still an evolving situation. Total revenues from that region account for roughly 3% of group revenues, yet the region also serves as a central hub within the global supply chain. As a result, the complete impact of these events is arguably unknown at present. Turning to gross margins, we are guiding to 62% for this year, which is 340 bps above FY '25 reported margins and 110 bps above the see-through margin discussed earlier. We have confidence that additional margin benefits will come from adopting the CapEx first pricing model together with improving recycling rates at the PromethION flow cell, which appears set to deliver further overall improvements and to offset anticipated headwinds related to product mix and currency.

Nicholas Keher

executive
#19

For adjusted OpEx growth, our guidance sits at 0% to 5%, and that captures the benefits we anticipate from the strategic realignment exercise in November plus our ongoing push to lift efficiencies across the business as a whole. That range also mirrors the timing of hiring we expect throughout the business. As we move through '26 and '27, we see chances to further enhance operational efficiency through non-headcount-related activities as well, especially in logistics and IT. Now to my last slide, covering financial outlook and summary. Worth noting we are reiterating our medium-term adjusted EBITDA and cash flow guidance targets at '27 and '28, respectively, though with revised constituent drivers for how we will get there. We expect that strong, above-market, broad-based revenue growth in '26 to carry on in '27 at a broadly similar rate. Such growth sits below the medium-term CAGR of over 30% set previously, reflecting a mix of a weaker end market backdrop than when guidance was first set and partly execution, which we will look to improve going forward. We delivered a 26% improvement in adjusted EBITDA in '25, and we continue to see additional operational leverage in '26 and '27 that will deliver adjusted EBITDA breakeven consistent with our medium-term guidance.

Nicholas Keher

executive
#20

With the gross margin trend improving and moving faster than we originally expected, plus the restructuring work finished in '27—finished in—sorry, and with that better gross margin trend beating our initial expectations along with restructuring efforts bringing further operational efficiencies, we still expect breakeven EBITDA in '27, and that view holds even if top line growth comes in lower. Also, as we showed today, we keep converting our operational results into genuine cash improvements. Our cash burn fell by GBP 50 million during the year. That pattern should carry on through '26 and '27, helped by smaller losses, uptake of the CapEx model, and additional working capital benefits still to come, and we still foresee cash flow breakeven in '28 with a minimum cash position above GBP 100 million. Before I hand things back to Gordon for closing remarks, I'd also like to offer my own personal thanks to Gordon and say congratulations on a truly remarkable achievement in building a great company like Oxford Nanopore.

Gordon Sanghera

executive
#21

Thanks, Nick. So we’re on the last slide now, and it’s up. After 21 years at this — at the helm — I just wanted to say a few words. I’ve always felt this was a deep tech company. People talk about that a lot. It actually took us 10 years to deliver our first products. We’ve been in the marketplace 10 years, and we’ve raised a lot of money, and people look at that and they think the return on the investment is low, but this company will be around in 100 years’ time. Already today, T2T genomes are the new gold standard. And you can’t get any better than that, because it’s the whole genome completely mapped. And Craig Venter, who is the founder of the original — driver of the original human genome, is out there building that gold standard. So as I reflect on this 20-year journey, it will never work. You’ll never make a circuit, you can’t stabilize a soap bubble, you can’t raise money in London, you can’t float in London, you will never be profitable — all these things just made us more determined, and this is the right moment to hand over. I’ve always known this moment will come.

Gordon Sanghera

executive
#22

This company is going to grow much larger than any single person. Still, it’s every individual who over the past 21 years genuinely believed we were capable of achieving something distinctive and special — and we did. This is a truly thrilling moment. I’m genuinely enthusiastic about Francis joining us, picking up the baton, and truly helping to build this company and carry us to the next level. I want to thank all of you. It has been a wonderful ride and journey, and I want to thank the Board, especially for tolerating me across 5 years. I’ll close with this: I am not retiring. As David Bowie put it on his 50th birthday, I don’t know what I’ll do next, but I can promise it will be interesting. Thank you so much.

Nicholas Keher

executive
#23

Any questions? Zain, would you mind stating your name and the company you're with?

Zain Ebrahim

analyst
#24

Zain Ebrahim from JPMorgan. First off, I'd like to add my congratulations to Gordon too, on your legacy and all that you've built here. My first question concerns the '26 guidance—specifically the moving parts you discussed regarding the revenue guide to some extent, but please elaborate further on what takes us to the top end of that guidance versus the bottom end. P2i Solo sounds like a major factor when it comes to conversion, but from a geographic standpoint as well, what makes you confident that the Americas will outgrow or see accelerating growth compared with 2025? That's my first question. My second question is about the adjusted EBITDA route to breakeven. You mentioned the operational leverage you're able to drive, but could you give a bit more detail on where you expect gross margin to land? Consensus shows an adjusted EBITDA loss of GBP 14 million for next year. So what do you believe we in consensus are failing to appreciate?

Nicholas Keher

executive
#25

Turning to the '26 revenue guidance. Geographically, why do we feel good about the Americas? There's momentum there. When we run the process of setting guidance, plenty of factors come into play. Specifically, in the non-research markets, looking at pipeline coverage and the raw count of customers — those prominent ones in clinical or biopharma are evaluating, and they're also lined up to adopt product. Yes, I'd say our confidence in the Americas market is there and that we've turned that corner now. Penetrating the U.S. research market has always been tough for us, for any number of possible reasons. But the applied markets have gotten there faster. We've mentioned that more than 50% of revenue in the Americas now comes from those applied markets, and that looks set to continue. So a different kind of customer is buying the product, they're reaching scale, and they're driving the growth. On EMEA, we covered this in the statement, but even just looking at the 5-year historic CAGR for EMEA, that's been one hell of a performance, and the team has done a great job in terms of how they've delivered that growth consistently year-on-year.

Nicholas Keher

executive
#26

Looking ahead to this year, a few contracts are rolling off that we’ve discussed, such as NIHR and GL 2.0. The U.K. Biobank contract is coming in and will help offset that, but it means a portion of revenue is basically flat for the year. So that’s a piece we simply have to factor in. As a result, it may just be — we expect overall growth to be lower this year. As always, we also aim to set guidance prudently. Now for APAC, this is probably where there’s more of a wildcard element at play. We are seeing conversion, especially in certain markets to clinical, that is actually quite encouraging. So adaptive sampling is making meaningful inroads with some large customers, particularly in Australia. And there’s a healthy pipeline of activity that we’re pursuing. But there is simply a timing aspect to how things ramp up. And we’ve seen that it can take time for these things to reach the scale we want. At the same time, we have precise II, which has ended and is coming off.

Nicholas Keher

executive
#27

So in those markets outside China, those dynamics are visible. Within China itself, I think several things are going on. First, the export control restrictions have not become any easier. And because of the restrictions that are in place, we now have a backlog of potential revenue for that market. We could also acknowledge that there are — well, there are more Nanopore competitors in the China market as well. We've assessed those technologies against ours. Our technology, we believe, is superior, and that is shown by the fact that even with the price differential being what it is in that market, you still see high underlying demand for our technology overall, but it is something that has kind of grown over the recent years. And then finally, from an execution standpoint, we think we can do better. And China is a substantial part of APAC overall. So we're setting guidance cautiously. That's why I talk about it being potentially a surprise to the upside. And hopefully, as we progress through the year, as we improve upon that, and we get greater confidence, maybe we can look again. In terms of product level as well, because you asked about the P2i — P2S piece, so we're setting guidance of 21% to 25% growth.

Nicholas Keher

executive
#28

We are embedding some risk there around the P2 Solo being discontinued, in case that shift over to the P2i doesn't materialize the way we expect it to. So in carrying out this commercial realignment exercise, we took the 47 end market segments that we target, the high priority segments across the board. We then assessed what customers demand in terms of requirements, the table stakes, as we look at those high priority segments. And what we found is that the P2i fits better. The P2 Solo is a very good product, but overall the P2i is the better fit for customers. And we're going to push the P2i stronger and harder than before, because we believe our customers will get a better experience overall as well. So we've made a tough decision. We're focusing efforts from a commercial market -- and that's the big C of commercial -- sorry, sales, marketing, all of the efforts, application development, workflow development, all of that on the P2i or the P24, so that we essentially get a better return overall for the company and drive faster, more profitable growth. Now there is a risk, though, in the interim that this essentially drives somewhat weaker performance as we execute on that.

Nicholas Keher

executive
#29

So part of my responsibility is ensuring that consideration has been baked into the guidance as a whole, and ideally that is what we have accomplished. Turning to adjusted EBITDA breakeven, what is the market overlooking? When I look at consensus as of today, and it is being updated, earlier on, I think the market had a question mark hanging over that top line growth rate. To be clear, at the time we laid out medium-term guidance, it was always breakeven adjusted EBITDA in '27, cash flow in '28, and we provided the constituent drivers so the market could model how they would arrive there. We also stated that if top line growth was not delivering what we wanted, we would in fact modulate the cost base accordingly. That is precisely what we have done. We have 2 examples of that from the year just gone. And now, through those exercises, in fact, we do not need to hit over 30% CAGR to reach that breakeven in '27. So ideally, the market comes away from this thinking, actually, with the new guidance that is out today — actually, sorry, medium-term is reiterated, but with the updated constituent parts, it is in fact a more realistic outlook for achieving adjusted EBITDA breakeven in '27. And ideally, investors and analysts can begin to model that in as well.

Veronika Dubajova

analyst
#30

Veronika Dubajova with Citi here. I have a couple of questions for you both, if I may. The first actually takes us back to that EBITDA breakeven path, Nick. Could you perhaps expand a bit on the gross margin picture specifically? Because by my calculation, you would need to land above the 62% figure we discussed before in order to reach that breakeven point. Maybe just walk us through how we arrive there in 2027, and what underpins your greater confidence that it can be done? Then my second question is more big picture, and it's for both you, Gordon, and Nick: now that the strategic realignment has happened and you've had it settling in across the organization for several months since the restructuring, just talk us through which pieces excite you the most? How is the organization coping with that change, and is there anything that has perhaps turned out better or worse than you anticipated? And last, congratulations from me as well, Gordon. We're eager to hear more from you in your new advisory position — but what an incredible achievement, and I hope you get to enjoy a bit of downtime.

Nicholas Keher

executive
#31

Thanks, Veronika. Turning to the EBITDA breakeven topic, and looking specifically at gross margin: yes, absolutely. What we have guided to today is a 62% gross margin for FY '26. That moves forward the original constituent guidance point of greater than 62% in '27. So we are pulling that ahead by a year. And in the statement, we believe continued improvements will be seen as we go into '27. I think it is fair to assume that this means the market can start thinking about 64% for '27 as an achievable gross margin, or perhaps around that level. The reason we are confident on that is that when we set the original guidance in '24, we did state to the market that -- sorry, we have not updated the pricing model. The pricing model changes and going CapEx first has clearly delivered a benefit on gross margin overall. And so we are updating for that. The piece that still has to deliver a true tailwind, and it will because we are seeing it, is in PromethION flow cell recycling. So in the year just gone, the drop in MinION recycling essentially canceled out the benefit we saw in PromethION. For this year going forward, the MinION recycling rate is now at a level that actually will step over that.

Nicholas Keher

executive
#32

However, as PromethION ramps up, that will bring a meaningful boost to gross margins overall. We've discussed this previously, but if the MinION level — if we hit the levels we reached with the Prom relative to the Min — then basically, it could mean a 10 percentage point improvement on PromethION gross margins overall. There's still some distance to travel there. So that's the path to getting there. On the bigger picture piece, would you like to start, Gordon?

Gordon Sanghera

executive
#33

Nope, please continue.

Nicholas Keher

executive
#34

The strategic realignment piece and parts of that, I find exciting. From my own perspective and my opinion on it, I think prioritizing activities will always lead to better outcomes. And so the team — we have got incredible capability in the business. And because the technology is so good, there is almost so much we can work on. And I think that is genuinely what I mean I have seen since I have been here: there is just so much opportunity for the technology to go on, 47 end market segments, it could arguably go with all of them. I think actually having this kind of focus prioritized exercise completed and saying, well, we are going to have to put down tools here because we are going to focus there is a good thing for the business. And actually, it is going to drive increased efficiency overall because we can have more people working on those bigger projects that are going to move the dial as well. So that is the part I am excited about. Clearly, going through change as a business, it is difficult, actually. And so I do not want to — I think it has been hard, actually. And these things take time to work through. But even since the start of the year, people are starting to kind of find their feet again and kind of realign to what that is.

Nicholas Keher

executive
#35

As always, not everyone has arrived at that point yet, but we are working our way through it. And I believe we will reach that point.

Gordon Sanghera

executive
#36

Success can be painful when possibilities are infinite — that's what occurs once the impossible becomes possible. And a finite resource presents a challenge. The company has, quite rightly, been evolving toward far greater focus on the 5 or 10 big things. We're redesigning the PromethION chip so it can be reused, which brings radical, transformative gains in revenue and margin, rather than saying, "oh, we can reuse it even though it wasn't designed for reuse." So our confidence in that trajectory is very high. Adaptive sampling is going to be groundbreaking and transformative. Here the DNA, in the first seconds, is read, and the sequencer is intelligent enough to determine whether that region is of interest — on target or off target. That means 2 days and $300 to $500 of target enrichment vanishes. But beyond that, since you're examining native DNA, you wind up seeing methylation. 2026 will be the year of the methanone — the UK Biobank and the Office of Life Sciences, together with Nanopore, are sequencing 50,000 patient samples. That will deliver the first and most comprehensive 5-base genome. That fifth base matters incredibly, scientifically. Now, I could keep going — the list is endless — but what we've done is target 3 to 5 major things: direct RNA with mods, direct DNA with mods, adaptive sampling, and reuse by design.

Gordon Sanghera

executive
#37

So every one of those major drivers adds up to the fact that doing everything we'd like isn't possible. It's simply a natural shift as we move from a company that's heavy on R with a bit of D into a proper R outfit that carries a great deal of D, given the applied and regulated end markets we serve — which is what delivers recurring, sticky revenue across multiple years and fundamentally transforms how people use NGS, since these are workflows that nobody but us can enable. That whole set of things is what excites me, what will bring about change, and what will matter for our growth trajectory.

Sam England

analyst
#38

This is Sam England calling from Berenberg. To begin with, regarding the 2026 revenue guidance: could you help us understand how growth and margins will be paced across 2026? Specifically, is there anything on the revenue side or the cost side that we ought to keep in mind when it comes to how this year is phased? Then, zooming out, could you update us on where you stand with biopharma QC? In particular, are potential clients showing greater interest at this point? And is there anything you can share about the potential for landing large contracts during 2026? I know that's a topic you raised at points over the course of '25. And finally, simply to add to what everyone else has said: congratulations, Gordon, and the very best of luck going forward.

Nicholas Keher

executive
#39

Tom, turning to 2026 revenue cadence, margins and costs. As in prior years, we expect revenue to split broadly 45-55 between the first half and second half, consistent with what we've seen. So it's good to make sure everyone has the numbers placed correctly for that. Then on margins, I think there are a few moving parts overall. But actually, we might see gross broadly consistent half-on-half. So very much a 62% level is what we're aiming for, for both the first half and the second half. On cost phasing, we've just had the benefit of the November restructuring event. So you'll see some benefit from that in the first half as well. But in terms of adjusted EBITDA loss, it will mirror that revenue performance too. I expect us to show meaningful year-on-year adjusted EBITDA improvement. And if people plug through those numbers we've put in our guidance today, the market should work out at circa a negative GBP 45 million to GBP 55 million loss for the year in adjusted EBITDA, which is, I think, quite a meaningful improvement on the year just gone and good against where consensus sits at the moment as well.

Nicholas Keher

executive
#40

On the second one, biopharma QC, Gordon and I have felt a lot of frustration at not being able, from a commercial standpoint, to identify the companies in this space that are developing the technology, but you can be sure that things are moving forward. So when it comes to mRNA vaccine production, we've signed a contract there. There's another one we hope to sign this year. On the sterility side, we have another deal we've discussed before and mentioned in today's statement — a large European biopharma that uses our technology centrally across several sites it manages. In time, that should extend out to those several sites too. So — and we also have a pipeline of companies evaluating the technology. So on confidence levels, biopharma QC is an area where, as time goes on, we'll see deeper penetration, and there's a big market opportunity for us to capture there. It's really frustrating that we can't just discuss the companies directly, who they are. But I'm certain those eagle-eyed analysts out there will manage to figure it out over time. Gordon?

Gordon Sanghera

executive
#41

So I believe we issued a fee-for-service agreement with Eurofins — they took on our contract, handling sequencing for biopharma QC and sterility testing. Within the first 3 weeks, they detected a customer contamination issue that saved several millions, and that's really just a hint of what's coming. They didn't disclose who the customer was. But you're getting these glimpses, and it's frustrating because we have a strong roster of partners we aren't able to discuss.

Charles Weston

analyst
#42

Charles Weston from RBC here, with two questions. First, regarding the guidance: you noted in the release that revenue growth expectations for 2027 would be roughly comparable to 2026. You cited several 2026 headwinds that are fairly specific to that year, and naturally in 2027 you'll be working from a larger base in the nonresearch markets, which are expanding more quickly. So why shouldn't an acceleration in growth be expected for 2027? Second, a couple of product-specific items. To start, what's the timing for the Q line GridION version 2? You indicated 2026, but when exactly should we expect it? And the PromethION 2 genome flow cell, or chemistry — when should that arrive?

Nicholas Keher

executive
#43

Okay, regarding the guide — so 2027 has the potential to come in above 2026. That's possible. As far as what we're guiding to today, our message is that it will be a rate broadly similar to the one we see in 2026. And as far as the market goes, that's all that's needed for adjusted EBITDA breakeven in 2027. So what we're really trying to do here is land on a prudent set of market expectations, matching what's already out in the market as well. You're not wrong that we may see — sorry, given the growth in the applied markets and the weighting it carries, I can't — do we see anything that would be wrong, anything that's going to slow this growth down over time? No, not necessarily, but our purpose here is to kind of give '26 guidance and show how people can get to '27 breakeven and keep that in place. We'll update explicitly on '27 guidance when we get to 2027. On the timing of GridION version 2 — so, the second half of this year. And then on PromethION 2 genomes per flow cell. Actually, in — through beta testing with customers, we can already demonstrate this. We're just thinking about how we roll this out from a product perspective, effectively, to our customers, and that's the key piece there.

Nicholas Keher

executive
#44

It's not simply about having a flow cell capable of doing this—you actually need every one of the component pieces to turn it into a complete product for companies too. And we have to be cautious here. I don't want folks running off with the impression that every part of our business will get there, because with the PromethION flow cell and that particular focus, this will only suit specific customer segments. So you have to ask what the sample type is, what read length is involved, and what the customer is doing with the product. That's where it gets used initially, and after that we need to carry out additional development work so that all customers can benefit from it too. Gordon, is there anything you'd like to add?

Gordon Sanghera

executive
#45

No, I really think it matters a lot that there's this awful situation with every other competitor racing to the bottom on whole genomes. That's not what this is about. We've got biopharma applications, clinical applications, and other applied market applications in there where that throughput is going to be competitive with the incumbents, and that's where we'll deploy it. Not everyone requires that excess capacity. So this is a great illustration of how we're maturing considerably as a business and thinking about target customers and how to stratify them properly. Someone else in another place wants far lower throughput but far higher accuracy. So we're just beginning to really segment the markets, and we're at the start of that journey, and then targeting the right products in our portfolio to meet that.

Charles Weston

analyst
#46

Congrats, Gordon. Wishing you the best of luck in whatever comes next.

Analyst

analyst
#47

And then a couple that are a bit more specific. I was just wondering about the decline in MinION recycling — what was behind that?

Nicholas Keher

executive
#48

Nothing unusual there, I think that's the main point. Essentially, with the MinION, what we've observed is that among customers using the MinION product — since there are plenty of MinION devices out there and they tend to be lower-volume customers — getting those flow cells returned from the customer is harder than it is with the PromethION. So the stockpiles basically rise and fall, essentially, in terms of how much recycling we do. It also comes down to what we're focused on internally on the manufacturing side as well. So we can dial it up or down. So this is within our control. So we can look to raise or lower recycling rates as appropriate to make sure other factors are handled too, not only margin, but yes, there's nothing untoward. And we could raise it again. We can lower it. It really just depends on where we are.

Analyst

analyst
#49

Great. And on the inventory side, I’m just curious how much further reduction might still be possible there?

Nicholas Keher

executive
#50

Right. So managing our inventory levels is a major priority, from the Board right down through the organization. I think it's fair to say we can still work through it. We reported a GBP 80 million figure, but there are clearly provisions sitting against that as well. So the gross number is in fact higher. And there's room to work through this inventory position across the years ahead, with particular attention on the MinION flow cell range, while keeping the PromethION where it is. Several different factors feed into this. One is yield improvements. The more our yields rise, the less product we'll need, which means we can work through the inventory level. The other is the recycling rate, which actually works against the inventory level. Because the more recycling you can do, the less you chew through from an inventory standpoint as well. But looking ahead, there is absolutely scope to further improve and bring that inventory level down by tens of millions over time on a gross basis. And as I think we've discussed with you previously, we've got cash stored up there. We should unlock it.

Analyst

analyst
#51

Absolutely. Nice work, Gordon. It has been quite a while since we made that first IP to IPO investment.

Miles Dixon

analyst
#52

Miles Dixon from Peel Hunt, with three quick questions if I may. First, regarding those restructuring programs — Nick, you've already discussed where the focus lies, but forgive me, I don't have those figures in front of me. It seemed as though both headcount and cost stayed roughly level within R&D. So does that mean the real change is something else? Are we seeing a greater share directed toward chemistries and products that already exist? And is the point that less is going into genuine blue sky research? On a related note, we witnessed a truly passionate presentation on the proteomics product at the London calling event. What are you actually considering when it comes to the time line for bringing an offering like that to market? And if you could hint at what kind of R&D spend might be allocated toward something of that sort, that would be great. Then finally, on the clinical definition — you've evidently seen a 60% increase in sales into clinical, but what genuinely counts as clinical, since a very significant chunk of that revenue could in fact be a clinical research application. I'd just like a somewhat better understanding of that.

Nicholas Keher

executive
#53

Alright, the third one is probably the simplest to tackle first, and it comes down to how we define clinical and which customers fall into that group — it's anyone who uses the technology to give a patient a diagnosis. Obviously, we don't have a full picture of what everyone is doing with all of our technology at any given moment. That's something we're working on. And once we have it, I think segmenting our marketing approach will be quite interesting for us. So what we need to do is simply examine how the customer gets paid. Essentially, when we sell these products to customers who are basically in the clinical space and who earn their money from providing diagnoses to patients as well, that's the way we have to define it. So at times there could be a mix with translational work in there, because there's always going to be some grayness around how they overlap. Unfortunately, you're never going to get perfect reporting on this.

Gordon Sanghera

executive
#54

On that point, Nick — there's diagnosis, yes, but screening exists too. So let me be clear: most of the revenue comes from LDTs that have been clear-waived, where the physician authorizes the test rather than Oxford Nanopore supplying a diagnostic tool and workflow.

Nicholas Keher

executive
#55

Apologies. Right, that's good — and from a legal standpoint, worth catching. Then, regarding the first item on restructuring: if you look at R&D headcount, there's a bit of a mixed picture here, as Gordon has mentioned. We've made fairly substantial investments in areas such as tech transfer and later-stage development opportunities. But on average headcount — keep in mind we did a restructuring at the start of the year and reinvested in higher activities and areas like late-stage development, quality manufacturing, some of which sometimes sit within the R&D line. Then near the end of the year, in November, and the headcount reductions that took place there, you still see the average benefit coming through. So in fact, from an average standpoint you will see R&D headcount come down next year, but we are reinvesting. So we're going to — we're not — it's very important that you and the investors also take away that we're not halting innovation. We are absolutely putting money into the technology to drive future revenue growth as well. What we're trying to do is simply drive that prioritization.

Nicholas Keher

executive
#56

So we actually see a stronger return there. And what about proteomics?

Gordon Sanghera

executive
#57

On proteomics — we're genuinely thrilled that peptide mapping is now within reach. True protein sequencing is still ahead of us. At present, though, we've got what we refer to as our early open access program request for information, and some truly compelling potential applications have come in. There's a limit to how much of that we can discuss, since many of those are biopharma customers. Even so, the enthusiasm is considerable. Take all GLP-1s — they're essentially collections of peptides, correct? And we can read those directly now at the single-molecule level. No one else is capable of that. It's fairly revolutionary. We're still getting our bearings within that very early open access program — figuring out where and who can pursue some intriguing work to begin demonstrating where the potential market lies for this novel approach to leucine protein peptides.

Nicholas Keher

executive
#58

On the cost side as well. So today it's single-digit millions. But the key point is that all of this is a platform technology. And so while it might be directly single million pounds, essentially, that's because the broader technology already exists to basically build on top of.

Miles Dixon

analyst
#59

So what I'm really getting at is this: are we looking at something that plays out over 2 to 4 years, or does that kind of offering on the platform, if you will, take 5 to 10 years?

Gordon Sanghera

executive
#60

As far as pure-play protein sequencing goes, that's a medium-term proposition — 3 to 5 years out. With peptide mapping, though, certain revenue chances could arrive sooner rather than later. The thing is, we can't say what those will be yet, since we're building an entirely new market space along with a brand-new sensing element. We simply have to work our way through it. That said, we aren't just — what we're seeing is some excellent lone wolf academic applications, and we're also seeing significant corporate interest — quite a lot of corporate interest. So things should move faster than I believe the DNA burn down did, though it's difficult to predict at this moment.

Miles Dixon

analyst
#61

And, like everyone else, I want to say again — congratulations, Gordon.

Andrew Whitney

analyst
#62

Andrew Whitney here, from Investec. Let me piggyback on what Miles asked. I'm just trying to get at the overall philosophy of the business. With that small adjustment to near-term spending, does it mean you'll remain concentrated on a nuclear basis for a longer stretch before moving into proteins and metabolites? Should we, when we look at you over the midterm, view you as a nuclear-focused business to a greater degree than we did previously? Or have the timelines for some of those items stayed the same? Those really don't hinge on near-term spending, do they? What they hinge on is market opportunity, or whatever else it might be. So should we think of a nuclear basis for the foreseeable future and direct all our thinking there? Or is there something else in play? Then my second one: I believe you mentioned some senior hiring, and maybe that's tied to thinking about when Francis has come on board, but where do you feel you need to add people?

Gordon Sanghera

executive
#63

I'll take that question first. Since I'm the manager this season but won't be here next season, I'm not going to begin advising Francis on who he ought to sign. That club is called Tottenham Hotspur. We can all see what a mess that is, right? But regarding what I said about volatile organic compounds and small metabolites, we made a strategic decision to pursue either biology or chemistry. We picked biology. So we did DNA, and 5 years later we did RNA. Now we have some genuinely excellent opportunities in peptide mapping. So that marks the start of proteomics in a way that's very different from everyone else, which is mostly mass spectrometry, and protein sequencing will follow. So we haven't made a deliberate effort to pursue chemistry at this time. So we're neither distracted nor held back by not doing chemistry. We're focused on multiomics and biology. And that has very much been the strategic rationale from day 1.

Nicholas Keher

executive
#64

Let me jump in on that too, since it ties directly to what Miles asked. We're putting a lot of thought into this area around what the correct product for the protein would actually be in the end markets we're targeting. So we're getting very focused on even what the features and benefits of this specifically need to deliver in order to win. Essentially, we're really — and again, there are loads of applications you could take this into. So whether it's the peptide sequencing piece or whole protein sequencing, meaning the peptide piece Gordon just spoke to, we're now looking at the applications, at what it needs to do to win, making sure the product can do that, making sure it's ready for launch, and getting a better launch profile when we actually go for it as well. And Duncan's probably in the best place to answer that.

Duncan Tatton-Brown

executive
#65

Maybe, as the coach here, since the departing coach can't comment, I'll offer a few words. I mean, speaking for the Board, I think it's quite evident in this business that the calibre of talent and the capabilities—especially in research and development—have been clear to the Board for a while now, and that's really to Gordon's credit, and others', for building it up. I think there's been genuine progress over the past 2 years in strengthening the commercial team, and again, credit to Gordon for bringing real talent into the business. I think the executive team at this point has a few gaps. So I think Francis has an opportunity to bring in additional talent to grow the business over the coming few years. But I think there's plenty of talent in the business, and it's just some gaps at the senior level. So the opportunities ahead are quite encouraging.

Andrew Whitney

analyst
#66

Nice work, Gordon.

Nicholas Keher

executive
#67

A couple of analysts have joined the call. So I believe we have roughly another 5 minutes, and we could take 1 or 2 of those questions, please, Sergei.

Operator

operator
#68

Sure. Kyle Mikson from Canaccord has the first question.

Kyle Mikson

analyst
#69

Congrats, Gordon, and I’m looking forward to talking with — meeting with Francis shortly. So I’ve got 2 questions, and I’ll combine them into 1 here. The first concerns device revenue in ’26. I’m just wondering whether you could sort of break down shipment expectations for the year as you move through this P2S to P2i conversion and other items, and also the pricing tailwinds, maybe from the CapEx model, that I would have thought had rolled off by now — but perhaps that’s giving more of a benefit this year too? And my second question is about the clinical end market, which grew nearly 60% in ’25. You’re clearly taking steps to keep up your strong execution there, but is that becoming a more competitive space, with long-read competitors and short-read competitors doing more in that market, such that it maybe has gotten more challenging to grow at that level going forward?

Nicholas Keher

executive
#70

Let me start with the first item, device revenue in '26, and what our expectations are there. I believe you're correct that we will indeed keep seeing gains from the pricing model. One important thing to point out is that when we altered the pricing model at the start of '25 — in January, as folks may recall, with it going live in February — we clearly caught our customers somewhat off guard by shifting from free device placement to, in essence, charging for the device. That shift meant we saw somewhat of a deceleration in device placements throughout all of '25, which, based on the data in front of us, appears as though it ought to turn around in '26. So we might — I think we will once again see stronger overall device revenue growth in '26 compared with consumable pull-through. Without question we'll get that wrong. But as we view it today, that is precisely what we should expect. And once more, on the pricing tailwind benefit, we're still going to see a little more on the margin here. There's some genuinely interesting stuff in deep accounting that I'll walk people through off-line regarding why that could be and why it will help margin, but especially on the larger devices, where we should see gross margins improving overall.

Nicholas Keher

executive
#71

Turning to the second piece—growth and competition in the clinical end market, which is sort of emerging there. Obviously, new competitors are coming into the market. I know Gordon will certainly have a perspective on this too. But I think it's key to acknowledge why we're growing even in the face of the legacy conventional technologies out there, whether short read or long read. It's the richness of the information that Nanopore sequencing delivers, the direct data that comes from examining—direct DNA, RNA, the methylation, the long read, the structural variations, all combined into one, which essentially means we can win today, along with the turnaround time. So those things don't change because of the evolving landscape we can see ahead of us today. So there's no reason we should necessarily slow down. And again, when I look at the Americas growth rate and I look at the customers evaluating or underpinning that growth, there are some big names in the clinical space looking at this.

Gordon Sanghera

executive
#72

Kyle, honestly, I see the competitive picture as genuinely favorable for Oxford Nanopore. Illumina has at last conceded that long reads matter, and they've brought out a synthetic long-read offering. That makes, I believe, number four for them. So, best of luck to them on that. We've got native long, ultra-long, super long, and short. That means whatever relength you're after on native DNA, we can deliver it. Methylation has likewise moved to center stage, and the fact that they're releasing a methylation profiler too is again an acknowledgment that those 20,000 publications and the foundational work we've established around multiomics carry weight. So as far as we're concerned, bring it on — native, direct, all in one read at one price is going to beat the market. We're eager for that landscape, that competitive landscape, and to show how our tech is superior.

Operator

operator
#73

Thanks. Regrettably, we've run out of time for questions today. So with that, I'll turn things back to Gordon for some closing comments.

Gordon Sanghera

executive
#74

I want to say thanks to all of you for spending time with us today, and also for your time across the past couple of years, and we'll see everyone in 6 months, with Francis and Nick leading the charge. Thanks to all of you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Oxford Nanopore Technologies plc transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Oxford Nanopore Technologies plc earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Oxford Nanopore Technologies plc or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.